TY - JOUR
T1 - Enumeration of deregulated miRNAs in liquid and tissue biopsies of cervical cancer
AU - Shukla, Vaibhav
AU - Varghese, Vinay Koshy
AU - Kabekkodu, Shama Prasada
AU - Mallya, Sandeep
AU - Chakrabarty, Sanjiban
AU - Jayaram, Pradyumna
AU - Pandey, Deeksha
AU - Banerjee, Sourjya
AU - Sharan, Krishna
AU - Satyamoorthy, Kapaettu
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Objective: The altered miRNAs expression in cervical cancer tissue can be a critical player during tumorigenesis, may contribute to tumor cell heterogeneity and may determine distinct phenotypes within the tumor. Recent studies have highlighted the role of circulating miRNAs as a minimally-invasive biomarker and its potential as biosignature to complement routine tissue-based procedures. Methods: In order to determine whether miRNAs in serum can indicate changes in cervical tissue specimens, we performed small RNA sequencing and selected miRNAs were validated using qRT-PCR in serum and tissue specimens (n = 115). Further, luciferase assay were performed to investigate the interactions between hsa-miR-409-3p and hsa-miR-454-3p binding sites on 3′UTR region of MTF2 and ST18 respectively. Results: We have identified a total of 14 differentially expressed miRNAs common in serum and tissue specimens. Among them, hsa-miR-17-5p, hsa-miR-32-5p and hsa-miR-454-3p were upregulated while, hsa-miR-409-3p was downregulated in serum and tissue of cervical cancer subjects. Our in-silico small RNA sequencing data analysis identified isomiRs and classified miRNA into clusters and subtypes (exonic, intronic and intergenic) with respect to the expression status in serum and tissue specimens. Expression level of hsa-miR-409-3p and hsa-miR-454-3p were inversely correlated with their target genes MTF2 and ST18 levels respectively in human cervical cancer specimens. Luciferase assay demonstrated that hsa-miR-409-3p and hsa-miR-454-3p functionally interacts with 3′-UTR of MTF2 and ST18 respectively to decrease their activity. Conclusion: Our results support the significant role of circulating miRNAs in disease dissemination and their potential utility as biosignatures of clinical relevance.
AB - Objective: The altered miRNAs expression in cervical cancer tissue can be a critical player during tumorigenesis, may contribute to tumor cell heterogeneity and may determine distinct phenotypes within the tumor. Recent studies have highlighted the role of circulating miRNAs as a minimally-invasive biomarker and its potential as biosignature to complement routine tissue-based procedures. Methods: In order to determine whether miRNAs in serum can indicate changes in cervical tissue specimens, we performed small RNA sequencing and selected miRNAs were validated using qRT-PCR in serum and tissue specimens (n = 115). Further, luciferase assay were performed to investigate the interactions between hsa-miR-409-3p and hsa-miR-454-3p binding sites on 3′UTR region of MTF2 and ST18 respectively. Results: We have identified a total of 14 differentially expressed miRNAs common in serum and tissue specimens. Among them, hsa-miR-17-5p, hsa-miR-32-5p and hsa-miR-454-3p were upregulated while, hsa-miR-409-3p was downregulated in serum and tissue of cervical cancer subjects. Our in-silico small RNA sequencing data analysis identified isomiRs and classified miRNA into clusters and subtypes (exonic, intronic and intergenic) with respect to the expression status in serum and tissue specimens. Expression level of hsa-miR-409-3p and hsa-miR-454-3p were inversely correlated with their target genes MTF2 and ST18 levels respectively in human cervical cancer specimens. Luciferase assay demonstrated that hsa-miR-409-3p and hsa-miR-454-3p functionally interacts with 3′-UTR of MTF2 and ST18 respectively to decrease their activity. Conclusion: Our results support the significant role of circulating miRNAs in disease dissemination and their potential utility as biosignatures of clinical relevance.
UR - http://www.scopus.com/inward/record.url?scp=85070699112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070699112&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2019.08.012
DO - 10.1016/j.ygyno.2019.08.012
M3 - Article
AN - SCOPUS:85070699112
SN - 0090-8258
VL - 155
SP - 135
EP - 143
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 1
ER -